NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: VERAXA Biotech BiTAC Cancer Therapy Cell Line Development
VERAXA Biotech announced the initiation of cell line development for its lead BiTAC T-cell engager program in collaboration with ATUM, aiming to improve tumor selectivity and reduce off-tumor toxicity. This move follows encouraging preclinical data presented at AACR 2026 and supports CMC development and future clinical studies.
VERAXA Biotech announced the start of cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, using Leap-In Transposase technology to generate stable clonal cell lines for IND/CTA-enabling activities and future clinical development.
The BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell, employing a conditional 'AND'-gated approach to reduce off-tumor toxicity.
The collaboration applies ATUM's Leap-In Transposase technology to generate stable clonal cell lines, which will support CMC development including early process, analytical and formulation development, and production of material for nonclinical studies.
Encouraging preclinical data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, which led to the initiation of cell line development.
The conditional 'AND'-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
The announcement was made on July 2, 2026.
The full press release is available at https://ibn.fm/FCIlk.
VERAXA Biotech is a company focused on discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats, built on scientific breakthroughs from EMBL.
VERAXA Biotech trades on NASDAQ under the ticker VRXA.